HOME >> MEDICINE >> NEWS
Dutch study highlights short-term and long-term options for treatment of tennis elbow

N.B. Please note that if you outside North America the embargo date for Lancet press material is 0001 hours UK time Friday 22 February 2002.

Authors of a study in this weeks issue of THE LANCET conclude that steroid injections offer the best short-term treatment for tennis elbow, with physiotherapy offering marginally better long-term results than a wait-and-see policy.

Tennis elbow (lateral epicondylitis) affects 1-3% of the adult population; symptoms usually last between 6 months and two years, with most patients making a full recovery. The condition is generally treated with corticosteroid injections or physiotherapy. However, Dutch clinical guidelines recommend a wait-and-see policy.

Nynke Smidt and colleagues from Vrije University, Amsterdam, Netherlands, studied patients with tennis elbow of at least 6 weeks duration who were recruited by family doctors. Patients were randomly allocated to 6 weeks of treatment with corticosteroid injections, physiotherapy, or a wait-and-see policy. Outcome measures included general improvement, severity of the main complaint (pain), elbow disability, and patients satisfaction. The severity of elbow complaints, grip strength, and pressure pain threshold were assessed; all outcomes were assessed at 3, 6, 12, 26, and 52 weeks.

185 patients took part in the study. Corticosteroid injections were substantially better than all other therapy options for all outcome measures at 6 weeks; success rates were 92% compared with 47% for physiotherapy and 32% for wait-and-see policy. However, recurrence rate in the injection group was high. Long-term differences between injections and physiotherapy were significantly in favour of physiotherapy; success rates at 52 weeks were 69% for injections, 91% for physiotherapy, and 83% for a wait-and-see policy. However, the better success rate for physiotherapy over a wait-and-see policy was not statistically significant.

Nynke Smidt Comment
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7611-4076
Lancet
21-Feb-2002


Page: 1 2

Related medicine news :

1. Dutch study highlights crying as risk factor for child abuse
2. Controlled study after Dutch caf fire highlights teen mental-health problems after disasters
3. Dutch study links tea drinking to reduced heart attack risk
4. Four researchers awarded Dutch Nobel Prize
5. "Dutch Nobel Prize" for three researchers
6. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
7. UMaine study looks at infants and chronic nighttime crying
8. Chronic pain treatments more effective when taken together, new study shows
9. UNC study: Most N.C. family practitioners engage in unrecognized community service
10. New study in Nature demonstrates protection against cell death during heart attack
11. UCSF study offers insight into human circadian rhythms

Post Your Comments:
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 The US represents ... this report. In 2013, GlobalData’s forecast estimates that sales of ... CRC market due to the high incidence of the disease, ... the 5EU, Japan, and China. Increased sales of CRC therapies ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... 2015 Increasing sophistication among enterprise buyers of language ... in 2015, says Moravia CMO, Renato ... by market research firm Common Sense Advisory, 15 percent ... translation and localization needs. "From a language industry perspective, ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
Cached News: